Pemetrexed and Avelumab in Treating Patients With MTAP-Deficient Metastatic Urothelial Cancer

Conditions:   Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant;   Infiltrating Bladder Urothelial Carcinoma With Glandular Differentiation;   Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation;   Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant;   Infiltr ating Bladder Urothelial Carcinoma, Plasmacytoid Variant;   Metastatic Urothelial Carcinoma;   MTAP Negative Interventions:   Drug: Avelumab;   Drug: Pemetrexed Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials